These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

990 related articles for article (PubMed ID: 21383296)

  • 1. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP.
    Shim H; Oh JI; Park SH; Jang S; Park CJ; Huh J; Suh C; Chi HS
    J Clin Pathol; 2013 May; 66(5):420-5. PubMed ID: 23610041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
    J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
    Takahashi H; Tomita N; Yokoyama M; Tsunoda S; Yano T; Murayama K; Hashimoto C; Tamura K; Sato K; Ishigatsubo Y
    Cancer; 2012 Sep; 118(17):4166-72. PubMed ID: 22213346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
    Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
    Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
    Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
    Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
    Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
    Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma].
    Yi SH; Xu Y; Zou DH; An G; Zhao YZ; Qi JY; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):307-12. PubMed ID: 19799125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab.
    Gaudio F; Giordano A; Perrone T; Pastore D; Curci P; Delia M; Napoli A; de' Risi C; Spina A; Ricco R; Liso V; Specchia G
    Acta Haematol; 2011; 126(1):44-51. PubMed ID: 21430371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
    Song MK; Chung JS; Sung-Yong O; Lee GW; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ; Shin DH; Yun EY
    Ann Hematol; 2010 Oct; 89(10):985-91. PubMed ID: 20428871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.
    Beltran BE; Castillo JJ; Morales D; de Mendoza FH; Quinones P; Miranda RN; Gallo A; Lopez-Ilasaca M; Butera JN; Sotomayor EM
    Am J Hematol; 2011 Aug; 86(8):663-7. PubMed ID: 21761432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
    Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
    Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.